HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00550238

Long-term pimavanserin safety for Parkinson-related psychosis

About this title

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Read the official source — NCT00550238
Medication studyAges 40+Multiple countriesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 40 years.

Listed locations
Gilbert and 134 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study clarity

Study information

Study start dateJuly 2007
Recruitment status
Completed
Enrollment listed in the registry
459
Sponsor
ACADIA Pharmaceuticals Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, France, Canada, ...
Age range
Over 40 Years
Official registry ID
NCT00550238
Official title
Show the full official title

A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Gilbert, United States · Phoenix, United States · Tucson, United States

128 more locations
  • Berkeley, United States
  • Carson, United States
  • Fountain Valley, United States
  • Fresno, United States
  • Irvine, United States
  • La Habra, United States
  • La Jolla, United States
  • Laguna Hills, United States
  • Loma Linda, United States
  • Oxnard, United States
  • Pasadena, United States
  • Reseda, United States
  • Sunnyvale, United States
  • Ventura, United States
  • Englewood, United States
  • Danbury, United States
  • Fairfield, United States
  • Farmington, United States
  • Boca Raton, United States
  • Bradenton, United States
  • Deerfield Beach, United States
  • Gainesville, United States
  • Jacksonville, United States
  • Miami, United States
  • Naples, United States
  • Orlando, United States
  • Ormond Beach, United States
  • Panama City, United States
  • Pompano Beach, United States
  • Port Charlotte, United States
  • Sarasota, United States
  • St. Petersburg, United States
  • Tampa, United States
  • Augusta, United States
  • Decatur, United States
  • Glenview, United States
  • Springfield, United States
  • Kansas City, United States
  • Louisville, United States
  • Scarborough, United States
  • Baltimore, United States
  • Boston, United States
  • Worcester, United States
  • Clinton Township, United States
  • Detroit, United States
  • East Lansing, United States
  • Roseville, United States
  • Traverse City, United States
  • West Bloomfield, United States
  • Columbia, United States
  • St Louis, United States
  • Missoula, United States
  • Toms River, United States
  • Albany, United States
  • Commack, United States
  • Kingston, United States
  • Rochester, United States
  • Asheville, United States
  • Charlotte, United States
  • Durham, United States
  • New Bern, United States
  • Salisbury, United States
  • Cincinnati, United States
  • Cleveland, United States
  • Columbus, United States
  • Toledo, United States
  • Greensburg, United States
  • Philadelphia, United States
  • Providence, United States
  • Brentwood, United States
  • Houston, United States
  • Salt Lake City, United States
  • Burlington, United States
  • Alexandria, United States
  • Richmond, United States
  • Roanoke, United States
  • Virginia Beach, United States
  • Kirkland, United States
  • Spokane, United States
  • Milwaukee, United States
  • Innsbruck, Austria
  • Vienna, Austria
  • Roeselare, Belgium
  • London, Canada
  • Ottawa, Canada
  • Clermont-Ferrand, France
  • Marseille, France
  • Nantes, France
  • Pessac, France
  • Strasbourg, France
  • Bangalore, India
  • Chennai, India
  • Hyderabad, India
  • Madurai, India
  • Mangalore, India
  • Mumbai, India
  • Pune, India
  • Visakhapatnam, India
  • Chieti, Italy
  • Grosseto, Italy
  • Rome, Italy
  • Bydgoszcz, Poland
  • Katowice, Poland
  • Lublin, Poland
  • Coimbra, Portugal
  • Lisbon, Portugal
  • Porto, Portugal
  • Kazan', Russia
  • Kirov, Russia
  • Moscow, Russia
  • Pyatigorsk, Russia
  • Saint Petersburg, Russia
  • Samara, Russia
  • Smolensk, Russia
  • Belgrade, Serbia
  • Novi Sad, Serbia
  • Stockholm, Sweden
  • Kharkiv, Ukraine
  • Kiev, Ukraine
  • Luhansk, Ukraine
  • Lviv, Ukraine
  • Vinnitsia, Ukraine
  • Barnsley, United Kingdom
  • Blackburn, United Kingdom
  • London, United Kingdom
  • Newcastle, United Kingdom
  • North Shields, United Kingdom
  • Russia
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is ACADIA Pharmaceuticals Inc.

Did this study involve medication?

Yes. The study involved medication, including Pimavanserin tartrate (ACP-103).

Who was this study for?

Listed age limits: from 40 years.

Want to explore more studies?

Explore studies